In recent years, a therapy with Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors is available for patients suffering from familial hypercholesterolemia or who are defined as very-high risk for the occurrence of cardiovascular events by the European Society of Cardiology guidelines on dyslipidemia [15,16]. Here, PCSK9 is linked to familial hypercholesterolemia.